BELLICUM PHARMACEUTICALS INC (BLCM) Fundamental Analysis & Valuation

NASDAQ:BLCM • US0794814048

Current stock price

0.622 USD
-0.07 (-9.72%)
At close:
0.6288 USD
+0.01 (+1.09%)
After Hours:

This BLCM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. BLCM Profitability Analysis

1.1 Basic Checks

  • In the past year BLCM has reported negative net income.
  • BLCM had a negative operating cash flow in the past year.
BLCM Yearly Net Income VS EBIT VS OCF VS FCFBLCM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M -80M -100M

1.2 Ratios

  • BLCM has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BLCM Yearly ROA, ROE, ROICBLCM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 500 1K 1.5K 2K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for BLCM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BLCM Yearly Profit, Operating, Gross MarginsBLCM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -10K -20K -30K -40K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. BLCM Health Analysis

2.1 Basic Checks

  • BLCM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for BLCM has been increased compared to 1 year ago.
  • There is no outstanding debt for BLCM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BLCM Yearly Shares OutstandingBLCM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2M 4M 6M 8M
BLCM Yearly Total Debt VS Total AssetsBLCM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

2.2 Solvency

  • BLCM has an Altman-Z score of -51.30. This is a bad value and indicates that BLCM is not financially healthy and even has some risk of bankruptcy.
  • BLCM has a Altman-Z score of -51.30. This is amonst the worse of the industry: BLCM underperforms 92.16% of its industry peers.
  • There is no outstanding debt for BLCM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -51.3
ROIC/WACCN/A
WACC8.6%
BLCM Yearly LT Debt VS Equity VS FCFBLCM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 50M -50M

2.3 Liquidity

  • A Current Ratio of 3.65 indicates that BLCM has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 3.65, BLCM is doing worse than 61.60% of the companies in the same industry.
  • BLCM has a Quick Ratio of 3.65. This indicates that BLCM is financially healthy and has no problem in meeting its short term obligations.
  • BLCM has a Quick ratio of 3.65. This is in the lower half of the industry: BLCM underperforms 60.64% of its industry peers.
Industry RankSector Rank
Current Ratio 3.65
Quick Ratio 3.65
BLCM Yearly Current Assets VS Current LiabilitesBLCM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. BLCM Growth Analysis

3.1 Past

  • The earnings per share for BLCM have decreased strongly by -183.10% in the last year.
  • The Revenue for BLCM has decreased by -75.68% in the past year. This is quite bad
  • The Revenue has been growing by 51.17% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-183.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4%
Revenue 1Y (TTM)-75.68%
Revenue growth 3Y-40.55%
Revenue growth 5Y51.17%
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, BLCM will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.54% on average per year.
  • Based on estimates for the next years, BLCM will show a very strong growth in Revenue. The Revenue will grow by 187.52% on average per year.
EPS Next Y38.37%
EPS Next 2Y26.89%
EPS Next 3Y19.89%
EPS Next 5Y13.54%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y187.52%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BLCM Yearly Revenue VS EstimatesBLCM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2027 50M 100M 150M 200M
BLCM Yearly EPS VS EstimatesBLCM Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

0

4. BLCM Valuation Analysis

4.1 Price/Earnings Ratio

  • BLCM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BLCM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BLCM Price Earnings VS Forward Price EarningsBLCM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BLCM Per share dataBLCM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

  • BLCM's earnings are expected to grow with 19.89% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.89%
EPS Next 3Y19.89%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BLCM Dividend Analysis

5.1 Amount

  • No dividends for BLCM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

BLCM Fundamentals: All Metrics, Ratios and Statistics

BELLICUM PHARMACEUTICALS INC

NASDAQ:BLCM (6/1/2023, 8:00:02 PM)

After market: 0.6288 +0.01 (+1.09%)

0.622

-0.07 (-9.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-11
Earnings (Next)08-09
Inst Owners0.06%
Inst Owner Change0%
Ins Owners53.88%
Ins Owner Change0%
Market Cap5.91M
Revenue(TTM)1.51M
Net Income(TTM)-25.48M
Analysts43.33
Price Target5.1 (719.94%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)51.92%
Min EPS beat(2)25.03%
Max EPS beat(2)78.81%
EPS beat(4)4
Avg EPS beat(4)62.53%
Min EPS beat(4)25.03%
Max EPS beat(4)81.53%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-222.22%
EPS NQ rev (3m)-45%
EPS NY rev (1m)0%
EPS NY rev (3m)46.15%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.92
P/FCF N/A
P/OCF N/A
P/B 0.47
P/tB 0.47
EV/EBITDA N/A
EPS(TTM)-0.82
EYN/A
EPS(NY)-0.32
Fwd EYN/A
FCF(TTM)-2.72
FCFYN/A
OCF(TTM)-2.72
OCFYN/A
SpS0.16
BVpS1.32
TBVpS1.32
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 211.11%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.65
Quick Ratio 3.65
Altman-Z -51.3
F-Score1
WACC8.6%
ROIC/WACCN/A
Cap/Depr(3y)80.14%
Cap/Depr(5y)54.37%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-183.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4%
EPS Next Y38.37%
EPS Next 2Y26.89%
EPS Next 3Y19.89%
EPS Next 5Y13.54%
Revenue 1Y (TTM)-75.68%
Revenue growth 3Y-40.55%
Revenue growth 5Y51.17%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y187.52%
EBIT growth 1Y-35.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y47.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.93%
OCF growth 3YN/A
OCF growth 5YN/A

BELLICUM PHARMACEUTICALS INC / BLCM Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BELLICUM PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 3 / 10 to BLCM.


What is the valuation status for BLCM stock?

ChartMill assigns a valuation rating of 3 / 10 to BELLICUM PHARMACEUTICALS INC (BLCM). This can be considered as Overvalued.


What is the profitability of BLCM stock?

BELLICUM PHARMACEUTICALS INC (BLCM) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for BLCM stock?

The Earnings per Share (EPS) of BELLICUM PHARMACEUTICALS INC (BLCM) is expected to grow by 38.37% in the next year.


Can you provide the dividend sustainability for BLCM stock?

The dividend rating of BELLICUM PHARMACEUTICALS INC (BLCM) is 0 / 10 and the dividend payout ratio is 0%.